ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)

CAPS Rating: 3 out of 5

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Recs

0
Player Avatar BruceInToronto (39.50) Submitted: 8/25/2009 4:15:06 PM : Outperform Start Price: $6.08 ACAD Score: -106.95

Phase three drug approval coming soon

Featured Broker Partners


Advertisement